Skip to main content
letter
. 2021 Aug 23;11(8):e506. doi: 10.1002/ctm2.506

FIGURE 3.

FIGURE 3

Cyst fluid protein candidates to distinguish Carcinoma/HGD group from Benign/LGD group. (A) Principal component analysis (PCA) to distinguish Carcinoma/HGD from Benign/LGD. The proteins included are CEACAM5, FCGBP, FN1, GSN, HP, HSPA5, ITIH4, KNG1, MYH9, SERPINF1, and pancreatic enzymes, including AMY1A, AMY2A, AMY2B, CELA2A, CELA2B, CPA1, CPB1, CTRB1, CTRB2, PNLIP, PRSS1, and PRSS2. (B) Correlation analysis of amylase‐normalized protein CEACAM5, FN1, GSN, HSPA5, ITIH4, and SERPINF1. (Spearman's correlation coefficient R interpretation: 0.3–0.5 fair, 0.5–0.7 moderate, 0.7–0.9 very strong, 1 perfect). C) Receiver operating characteristic (ROC) curves of the ratio‐based composite biomarker (CEACAM5/AMY, SERPINF1/AMY, and HSPA5/AMY). (D) Predicted probability of composite biomarker using logistic regression. The standard cutoff of 0.5 was used to determine a positive result